 | |
| Clinical data | |
|---|---|
| Other names | N-[(S)-Fenchyl]-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H37N3O3 |
| Molar mass | 439.600 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
MN-25 (UR-12) is a drug invented byBristol-Myers Squibb,[1] that acts as a reasonably selectiveagonist of peripheralcannabinoid receptors.[2] It has moderate affinity forCB2 receptors with aKi of 11 nM, but 22x lower affinity for the psychoactiveCB1 receptors with aKi of 245 nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with aKi of 8 nM at CB1 and 29 nM at CB2,[3][4] which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB2 (cf.JWH-018 vsJWH-007,JWH-081 vsJWH-098).[5][6]
Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid,Org 28611, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as inJWH-200 orA-796,260. Early compounds such as these have subsequently led to the development of many related indole-3-carboxamide cannabinoid ligands.[7][8][9][10]
